• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
Endogenex

Endogenex

Bringing New Energy to the Treatment of Type 2 Diabetes

  • T2D
  • ReCET
  • Patients
  • Clinical Providers
  • About Us
    • News
    • Contact
  • ReCET Study

Uncategorized

Endogenex

Endogenex™ Appoints Christopher Sorli as Chief Medical Officer

Endogenex

Endogenex™ Appoints Medical Device Executive, Stacey Pugh, Chief Executive Officer

7News Australia report: Clinical study evaluating technology to treat Type 2 Diabetes being expanded

Clinical study participant with Type 2 Diabetes shares his story

CBS Minnesota report: Mayo Clinic participates in study to evaluate novel Type 2 Diabetes treatment

  • Previous
  • Page 1
  • Page 2

* Caution: Exclusively a clinical investigational device. Limited by federal (or United States or similar) law to investigational use. Not for sale in any geography.

Please refer to your physician for additional information on the ReCET Procedure, ReCET System, and related risks.

Endogenex, Inc.
13755 1st Avenue North #100
Plymouth, MN 55441
+1 763-251-6820
info@endogenex.com

References

Terms of Use

Privacy Policy

Cookie Policy

EndogenexTM and ReCETTM are registered trademarks of Endogenex, Inc. in the United States and other countries. Copyright © 2025 Endogenex, Inc. All rights reserved.

  • LinkedIn
  • X
  • Vimeo